Coloplast Temettü

Temettü kriter kontrolleri 3/6

Coloplast 2.4% cari getiri oranına sahip temettü ödeyen bir şirkettir.

Anahtar bilgiler

2.3%

Temettü verimi

95%

Ödeme oranı

Sektör ortalama getirisi	2.4%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	DKK 21.000
Hisse başına kazanç	DKK 22.09
Temettü verim tahmini	2.7%

Son temettü güncellemeleri

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: COLOBC şirketinin hisse başına düşen temettüsü son 10 yıldır istikrarlıydı.

Büyüyen Temettü: COLOBC şirketinin temettü ödemeleri son 10 yıldır artış göstermektedir.

Piyasaya Karşı Temettü Getirisi

Coloplast Piyasaya Karşı Temettü Getirisi

COLOBC temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (COLOBC)	2.3%
Pazarın Alt %25'i (GB)	2.2%
Pazarın En İyi %25'i (GB)	5.8%
Sektör Ortalaması (Medical Equipment)	2.4%
Analist tahmini (COLOBC) (3 yıla kadar)	2.7%

Önemli Temettü: COLOBC 'in temettüsü ( 2.4% ), UK piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 2.11% ) daha yüksektir.

Yüksek Temettü: COLOBC 'in temettüsü ( 2.4% ), UK piyasasındaki temettü ödeyenlerin en üst %25'ine ( 5.54% ) kıyasla düşüktür.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Yüksek ödeme oranı ( 95% ) nedeniyle COLOBC 'un temettü ödemeleri kazançlar tarafından yeterince karşılanmıyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Yüksek nakit ödeme oranı ( 359.6% ) nedeniyle, COLOBC 'un temettü ödemeleri nakit akışları tarafından yeterince karşılanmıyor.

Coloplast Temettü

Temettü kriter kontrolleri 3/6

Anahtar bilgiler

Son temettü güncellemeleri

Coloplast A/S Approves the Distribution of Year-End Dividend

Upcoming dividend of kr.15.00 per share

Upcoming dividend of kr.14.00 per share

Recent updates

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

First half dividend of kr.5.00 announced

Second quarter 2024 earnings released: EPS: kr.5.57 (vs kr.5.44 in 2Q 2023)

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

Less than half of directors are independent

First quarter 2024 earnings released

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Less than half of directors are independent

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Less than half of directors are independent

Coloplast A/S Approves the Distribution of Year-End Dividend

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Full year 2023 earnings released

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Deputy Chairman recently bought kr.40m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings released: EPS: kr.5.99 (vs kr.6.07 in 3Q 2022)

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Upcoming dividend of kr.15.00 per share

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Third quarter 2022 earnings released

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Second quarter 2022 earnings released

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Independent Director Birgitte Nielsen has left the company

Upcoming dividend of kr.14.00 per share

Full year 2021 earnings released: EPS kr.22.67 (vs kr.19.74 in FY 2020)

Third quarter 2021 earnings released: EPS kr.5.89 (vs kr.4.69 in 3Q 2020)

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Second quarter 2021 earnings released

New 90-day low: kr.857

First quarter 2021 earnings released

New 90-day high: kr.999

Revenue beats expectations

New 90-day low: kr.886

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin